• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

3 Factors Fueling Hospital Drug Diversion, The Silent Partner in the Opioid Epidemic

by Jasmine Pennic 06/04/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

 

3 Factors Fueling Hospital Drug Diversion, The Silent Partner in the Opioid Epidemic

BD (Becton, Dickinson and Company), a global medical technology company, today released a first-of-its-kind report based on an independent national survey that examines drug diversion in U.S. hospitals, an underreported contributor to the opioid epidemic.

Defining Hospital Drug Diversion

Hospital drug diversion, when a healthcare worker “diverts” opiates or other controlled substances away from patients for personal use or sale remains a significant challenge that is largely underdiscussed. Left undetected, diversion can lead to patient safety issues, harm to the diverter, and significant risk for the organization.

The national opioid epidemic has reached unprecedented heights, with Americans now more likely to die from opioid overdose than in a car accident — nearly 200 people a day on average, according to a 2019 analysis by the National Safety Council.1 Between 10% and 15% of the general population will misuse substances in their lives, including healthcare workers with access to controlled substances.2 This creates a vulnerability beyond that of the general population, making diversion a very serious problem across hospitals and health systems.

3 Factors Driving Hospital Drug Diversion

The report revealed three key factors that contribute to drug diversion:

1. Denial of the problem in their own hospitals – Executives and providers (nurses, pharmacists, and anesthesiologists) may be in denial about the diversion problem in their own facilities. The majority of providers surveyed (85%) were concerned about drug diversion in U.S hospitals, but only 20% believe diversion is cause for concern where they work. Despite this, half of respondents report they have observed suspicious activity in their hospitals that may have been evidence of diversion.

2. Detection technology is critical – Health care professionals believe the tools they are using to detect diversion are only somewhat effective and expressed the need for improved real-time detection tools to identify diverters without generating false positives. Specifically, 59% of executives want more accurate data to reduce false positives; 54% would like artificial intelligence (AI) or machine learning technologies and advanced analytics; and, 53% would like to see mandatory diversion training. Hospital executives and providers believe that, if given the appropriate resources, diversion can be significantly reduced.

3. Stressful work environment – Both executives and providers believe hospitals are stressful work environments, which may be a contributing factor that can make health care providers vulnerable to substance misuse. In fact, 78% of providers have known a peer who seemed stressed, “to the breaking point.”

Why It Matters

“This report clearly shows how difficult the issue of drug diversion is to detect, as well as the challenges hospitals and health systems face with tracking and managing cases of diversion within their own facilities,” said Perry Flowers, vice president of Medical Affairs at BD. “Diversion is not a new problem in health care, but recent advancements in diversion tracking include machine learning to intelligently analyze opioid transactions and reduce false positives. Establishing a culture of open dialogue and reporting that encourages recovery may also be key to efforts that address diversion.”

Report Background/Methodology

The report — Health Care’s Hidden Epidemic: A Call to Action on Hospital Drug Diversion — is based on findings from an independent survey of 651 health care executives and providers commissioned by the BD Institute for Medication Management Excellence and conducted by KRC Research, a global public opinion research consultancy. The survey collected data and opinions between February 20-28, 2019, from hospital executives, hospital diversion managers, anesthesiologists, pharmacists, and pharmacy technicians and a diverse group of nurses.

The report also includes additional data and personal insights from clinical thought leaders to highlight barriers and solutions and bring context to the raw data. An included resource guide focuses more narrowly on ways to support hospitals as they address this problem – with guidance such as implementing machine learning and other technologies and improving diversion education and training. The overall goal of the report is to foster a national conversation on the best ways to address this silent crisis.

 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Artificial Intelligence, Health Systems, Machine Learning, medical technology, medication, Opioid Epidemic, patient safety, Pharmacy, risk

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |